ADCT-602

ADCT-602

About ADCT-602

ADCT-602 is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD22 conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD22-expresing cell, ADCT-602 is internalized into the cell where enzymes release the PBD-based warhead. CD22 is an attractive and clinically validated ADC target. CD22 is highly expressed on most malignant B-cells, including expression in greater than 90  percent of patients with B-cell acute lymphoblastic leukemia (ALL).

ADCT-602 is being evaluated in a Phase I/II clinical trial in patients with relapsed or refractory B-cell ALL (ClinicalTrials.gov Identifier NCT03698552). The trial is being led by The University of Texas MD Anderson Cancer Center.

CD22 Ilustration